See more : Mantex AB (publ) (MANTEX.ST) Income Statement Analysis – Financial Results
Complete financial analysis of RBC Bioscience Corporation (6848.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RBC Bioscience Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- OPTiM Corporation (3694.T) Income Statement Analysis – Financial Results
- Zhejiang Tuna Environmental Science & TechnologyCo.,Ltd. (603177.SS) Income Statement Analysis – Financial Results
- Amistar Corporation (AMTA) Income Statement Analysis – Financial Results
- Allied Digital Services Limited (ADSL.NS) Income Statement Analysis – Financial Results
- RHB Bank Berhad (RHBAF) Income Statement Analysis – Financial Results
RBC Bioscience Corporation (6848.TWO)
About RBC Bioscience Corporation
RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues; automated nucleic acid extractors; and nucleic acid extraction kits. The company sells its products through distributors. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 172.47M | 173.89M | 251.18M | 575.16M | 161.68M |
| Cost of Revenue | 99.57M | 100.89M | 134.11M | 274.84M | 94.78M |
| Gross Profit | 72.90M | 73.01M | 117.07M | 300.33M | 66.90M |
| Gross Profit Ratio | 42.27% | 41.98% | 46.61% | 52.22% | 41.38% |
| Research & Development | 10.84M | 15.74M | 16.39M | 22.24M | 8.79M |
| General & Administrative | 26.23M | 26.72M | 28.62M | 68.04M | 14.27M |
| Selling & Marketing | 21.18M | 22.90M | 23.82M | 21.67M | 24.26M |
| SG&A | 47.41M | 49.61M | 52.44M | 89.71M | 38.59M |
| Other Expenses | 0.00 | 4.57M | -5.97M | -9.49M | 19.52M |
| Operating Expenses | 58.36M | 65.35M | 68.83M | 111.94M | 19.52M |
| Cost & Expenses | 157.93M | 166.24M | 202.94M | 386.78M | 19.52M |
| Interest Income | 361.00K | 160.00K | 174.00K | 139.00K | 140.00K |
| Interest Expense | 10.00M | 7.57M | 6.33M | 1.18M | 1.01M |
| Depreciation & Amortization | 18.67M | 19.74M | 19.86M | 13.83M | 5.34M |
| EBITDA | 36.55M | 32.12M | 62.31M | 192.87M | 24.85M |
| EBITDA Ratio | 21.19% | 18.47% | 24.81% | 33.53% | 12.07% |
| Operating Income | 14.54M | 12.39M | 42.45M | 179.03M | 19.52M |
| Operating Income Ratio | 8.43% | 7.12% | 16.90% | 31.13% | 12.07% |
| Total Other Income/Expenses | -6.67M | -2.74M | -12.29M | -11.04M | -1.49M |
| Income Before Tax | 7.87M | 4.92M | 35.95M | 177.34M | 18.03M |
| Income Before Tax Ratio | 4.56% | 2.83% | 14.31% | 30.83% | 11.15% |
| Income Tax Expense | 1.44M | 1.14M | 7.22M | 35.44M | 3.57M |
| Net Income | 6.43M | 3.78M | 28.73M | 141.90M | 14.46M |
| Net Income Ratio | 3.73% | 2.17% | 11.44% | 24.67% | 8.94% |
| EPS | 0.49 | 0.29 | 2.43 | 12.82 | 1.83 |
| EPS Diluted | 0.49 | 0.29 | 2.34 | 11.80 | 1.76 |
| Weighted Avg Shares Out | 13.12M | 12.98M | 11.83M | 11.07M | 7.91M |
| Weighted Avg Shares Out (Dil) | 13.00M | 13.01M | 12.30M | 12.03M | 8.23M |
Source: https://incomestatements.info
Category: Stock Reports